PPARs: The vasculature, inflammation and hypertension

Current Opinion in Nephrology and Hypertension

Volumn 18, Issue 2, 2009, Pages 128-133

  Duan, Sheng Zhong ^a   Usher, Michael G ^a   Mortensen, Richard M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Atherosclerosis; Hypertension; Inflammation; Macrophages; Peroxisome proliferator activated receptors

Indexed keywords

ABC TRANSPORTER G1; CCAAT ENHANCER BINDING PROTEIN; CD36 ANTIGEN; CELL NUCLEUS RECEPTOR; CHEMOKINE RECEPTOR CCR2; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FRACTALKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN BCL 6; STAT3 PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL POLARITY; DISEASE COURSE; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; INNATE IMMUNITY; MACROPHAGE ACTIVATION; METABOLIC DISORDER; MONOCYTE; MULTIGENE FAMILY; NONHUMAN; OBESITY; PHENOTYPE; PRIORITY JOURNAL; VASCULARIZATION;

ANIMALS; ATHEROSCLEROSIS; CELL POLARITY; ENDOTHELIAL CELLS; HUMANS; HYPERTENSION; IMMUNITY, INNATE; INFLAMMATION; MACROPHAGES; MUSCLE, SMOOTH, VASCULAR; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS;

EID: 63849093637     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328325803b     Document Type: Article

References (54)

1. Ryan MJ, Didion SP, Mathur S, et al. PPAR(gamma) agonist rosiglitazone improves vascular function and lowers blood pressure in hypertensive transgenic mice. Hypertension 2004; 43:661-666.
2. Nicol CJ, Adachi M, Akiyama TE, Gonzalez FJ. PPARgamma in endothelial cells influences high fat diet-induced hypertension. Am J Hypertens 2005; 18:549-556.
3. Duan SZ, Ivashchenko CY, Whitesall SE, et al. Hypotension, lipodystrophy, and insulin resistance in generalized PPARgamma-deficient mice rescued from embryonic lethality. J Clin Invest 2007; 117:812-822.
4. Zhou Y, Luo P, Chang HH, et al. Colfibrate attenuates blood pressure and sodium retention in DOCA-salt hypertension. Kidney Int 2008; 74:1040-1048.
5. Takata Y, Liu J, Yin F, et al. PPARdelta-mediated antiinflammatory mechanisms inhibit angiotensin ll-accelerated atherosclerosis. Proc Natl Acad Sci U S A 2008; 105:4277-4282.
6. Libby P. Inflammation in atherosclerosis. Nature 2002; 420:868-874.
7. Liao TD, Yang XP, Liu YH, et al. Role of inflammation in the development of renal damage and dysfunction in angiotensin ll-induced hypertension. Hypertension 2008; 52:256-263.
8. Nava M, Quiroz Y, Vaziri N, Rodriguez-lturbe B. Melatonin reduces renal interstitial inflammation and improves hypertension in spontaneously hypertensive rats. Am J Physiol Renal Physiol 2003; 284:F447-F454.
9. Bensinger SJ, Tontonoz P. Integration of metabolism and inflammation by lipid-activated nuclear receptors. Nature 2008; 454:470-477.
10. Li AC, Binder CJ, Gutierrez A, et al. Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 2004; 114:1564-1576.
11. Chawla A, Boisvert WA, Lee CH, et al. A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 2001; 7:161-171.
12. Babaev VR, Ishiguro H, Ding L, et al. Macrophage expression of peroxisome proliterator-activated receptor-alpha reduces atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation 2007; 116:1404-1412.
13. Lee CH, Chawla A, Urbiztondo N, et al. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 2003; 302:453-457.
14. Barish GD, Atkins AR, Downes M, et al. PPARdelta regulates multiple proinflammatory pathways to suppress atherosclerosis. Proc Natl Acad Sci U S A 2008; 105:4271-4276.
15. Tesfamariam B, DeFelice AF. Endothelial injury in the initiation and progression of vascular disorders. Vascul Pharmacol 2007; 46:229-237.
16. Marx N, Mach F, Sauty A, et al. Peroxisome proliferator-activated receptor- gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and l-TAC in human endothelial cells. J Immunol 2000; 164:6503-6508.
17. Sasaki M, Jordan P, Welbourne T, et al. Troglitazone, a PPAR-gamma activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF-alpha. BMC Physiol 2005; 5:3.
18. Beyer AM, de Lange WJ, Halabi CM, et al. Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet. Circ Res 2008; 103:654-661.
19. Semple RK, Meirhaeghe A, Vidal-Puig AJ, et al. A dominant negative human peroxisome proliferator-activated receptor (PPAR){alpha} is a constitutive transcriptional corepressor and inhibits signaling through all PPAR isoforms. Endocrinology 2005; 146:1871-1882.
20. Marx N, Sukhova GK, Collins T, et al. PPARalpha activators inhibit cytokine- induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 1999; 99:3125-3131.
21. Fan Y, Wang Y, Tang Z, et al. Suppression of pro-inflammatory adhesion molecules by PPAR-delta in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 2008; 28:315-321.
22. Park KG, Lee KM, Chang YC, et al. The ascochlorin derivative, AS-6, inhibits TNF-alpha-induced adhesion molecule and chemokine expression in rat vascular smooth muscle cells. Life Sci 2006; 80:120-126.
23. Takata Y, Kitami Y, Yang ZH, et al. Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein- delta and peroxisome proliferator-activated receptor-gamma. Circ Res 2002; 91:427-433.
24. Gizard F, Nomiyama T, Zhao Y, et al. The PPAR{alpha}/p16INK4a pathway inhibits vascular smooth muscle cell proliferation by repressing cell cycle-dependent telomerase activation. Circ Res 2008; 103:1155-1163.
25. Gizard F, Amant C, Barbier O, et al. PPAR alpha inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a. J Clin Invest 2005; 115:3228-3238.
26. Delerive P, De Bosscher K, Besnard S, et al. Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factors NF-kappaB and AP-1. J Biol Chem 1999; 274:32048-32054.
27. Lim HJ, Lee S, Park JH, et al. PPARdelta agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle. Atherosclerosis 2008; 254:112-117.
28. Ravaux L, Denoyelle C, Monne C, et al. Inhibition of interleukin-1 beta-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator- activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPARbeta and the proto-oncogene BCL-6. Mol Cell Biol 2007; 27:8374-8387.
29. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr 2006; 83:456S-460S.
30. Rader DJ, Pure E. Lipoproteins, macrophage function, and atherosclerosis: beyond the foam cell? Cell Metab 2005; 1:223-230.
31. Shashkin P, Dragulev B, Ley K. Macrophage differentiation to foam cells. Curr Pharm Des 2005; 11:3061 -3072.
32. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004; 95:858-866.
33. Weisberg SP, Hunter D, Huber R, et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding. J Clin Invest 2006; 116:115-124.
34. Weisberg SP, McCann D, Desai M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112:1796-1808.
35. Swirski FK, Libby P, Aikawa E, et al. Ly-6Chi monocytes dominate hyperch-olesterolemia-associated monocytosis and give rise to macrophages in atheromata. J Clin Invest 2007; 117:195-205.
36. Swirski FK, Pittet MJ, Kircher MF, et al. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci U S A 2006; 103:10340-10345.
37. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3:23-35.
38. Arnold L, Henry A, Poron F, et al. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J Exp Med 2007; 204:1057-1069.
39. Nahrendorf M, Swirski FK, Aikawa E, et al. The healing myocardium sequentially mobilizes two monocyte subsets with divergent and complementary functions. J Exp Med 2007; 204:3037-3047.
40. Mills CD, Kincaid K, Alt JM, et al. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 2000; 164:6166-6173.
41. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391:82-86.
42. Ricote M, Huang J, Fajas L, et al. Expression of the peroxisome proliferator-activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1998; 95:7614-7619.
43. Berry A, Balard P, Coste A, et al. IL-13 induces expression of CD36 in human monocytes through PPARgamma activation. Eur J Immunol 2007; 37:1642- 1652.
44. Huang JT, Welch JS, Ricote M, et al. lnterleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999; 400:378-382.
45. Bouhlel MA, Derudas B, Rigamonti E, et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab 2007; 6:137-143.
46. Odegaard Jl, Ricardo-Gonzalez RR, Goforth MH, et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007; 447:1116-1120.
47. Hevener AL, Olefsky JM, Reichart D, et al. Macrophage PPAR gamma is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest 2007; 117:1658-1669.
48. Odegaard Jl, Ricardo-Gonzalez RR, Red Eagle A, et al. Alternative M2 activation of Kupffer cells by PPARdelta ameliorates obesity-induced insulin resistance. Cell Metab 2008; 7:496-507.
49. Kang K, Reilly SM, Karabacak V, et al. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab 2008; 7:485-495.
50. Gallardo-Soler A, Gomez-Nieto C, Campo ML, et al. Arginase I induction by modified lipoproteins in macrophages: a peroxisome proliferator-activated receptor-gamma/delta-mediated effect that links lipid metabolism and immunity. Mol Endocrinol 2008; 22:1394-1402.
51. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med 2007; 2:85-87.
52. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298:1189-1195.
53. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298:1180-1188.
54. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356:2457-2471.